Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Leerink Partners

Halozyme Therapeutics (NASDAQ:HALO) was upgraded by equities research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday. The brokerage presently has a $110.00 price objective on the biopharmaceutical company’s stock. Leerink Partners’ price objective would indicate a potential upside of 28.26% from the company’s current price.

A number of other equities analysts also recently commented on HALO. HC Wainwright lifted their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.60.

Halozyme Therapeutics Stock Performance

HALO opened at $85.76 on Friday. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $86.00. The firm has a market capitalization of $10.17 billion, a PE ratio of 30.85, a PEG ratio of 0.35 and a beta of 0.85. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The firm’s 50-day moving average price is $75.74 and its 200 day moving average price is $71.25.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC increased its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $28,000. Harbour Investments Inc. raised its position in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares during the period. Finally, Clearstead Advisors LLC raised its position in Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record quarterly results exceeded expectations. Second-quarter revenue rose 48% year over year to $481 million, beating estimates of approximately $402 million. Adjusted earnings reached $2.28 per diluted share, above consensus estimates ranging from $1.79 to $1.82 and up from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth remained a key catalyst. Royalty revenue increased 50% year over year to $308 million, highlighting continued commercial adoption of Halozyme’s drug-delivery technologies and the scalability of its royalty-based business. Halozyme Q2 Key Metrics
• Positive Sentiment: Management raised 2026 guidance. Halozyme now expects total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is well above the roughly $8.02 analyst consensus. Halozyme Q2 2026 Results Presentation
• Positive Sentiment: Business development exceeded targets. The company signed five new ENHANZE and Hypercon collaboration agreements during 2026, already surpassing its goal of three agreements for the full year. This could strengthen Halozyme’s longer-term pipeline and royalty growth prospects. Halozyme Q2 2026 Earnings Call Transcript

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.